子类别 期刊論文 [327/330] 圖書 [1/1] 會議論文/會議摘要 [115/179] 邻近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群统计 近3年内发表的文件:74(14.51%) 含全文笔数:443(86.86%) 文件下载次数统计 下载大于0次:443(100.00%) 下载大于100次:426(96.16%) 全文下载总次数:178131(3.32%) 最后更新时间: 2024-12-01 08:27 上传排行 数据加载中..... 下载排行 数据加载中..... 最近上传 Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

跳至: (选择年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (选择月份) January February March April May June July August September October November December 或输入年份:

由新到旧排序 由最旧的开始

显示项目26-50 / 510. (共21页) << < 1 2 3 4 5 6 7 8 9 10 > >> 每页显示[10|25|50]项目

日期	题名	關聯
2023-05-24	Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer	ESMO Open. 2023 May 24;8(3):Article number 101558.
2023-05-01	The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy	Experimental and Molecular Medicine. 2023 May;55(5):926-938.
2023-02-24	Deciphering the functions of telomerase reverse transcriptase in head and neck cancer	Biomedicines. 2023 Feb 24;11(3):Article number 691.
2023-02-05	Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer	Cancers. 2023 Feb 5;15(4):Article number 1008.
2023-02	The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan	ESMO Open. 2023 Feb;8(1):Article number 100746.
2023-01-21	Adjuvant therapy in biliary tract cancers: Oral fluoropyrimidine as a beginning	Lancet. 2023 Jan 21-27;401(10372):170-171.
2023-01-20	ARID1A loss in pancreas leads to islet developmental defect and metabolic disturbance	iScience. 2023 Jan 20;26(1):Article number 105881.
2023-01-19	Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma	New England Journal of Medicine. 2023 Jan 19;388(3):228-239.
2023-01-06	Visible CCD camera-guided photoacoustic imaging system for precise navigation during functional rat brain imaging	Biosensors. 2023 Jan 6;13(1):Article number 107.
2023-01	TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIdelta/AKT pathway	Journal of Advanced Research. 2023 Jan;43:45-57.
2022-12-28	Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan	Scientific Reports. 2022 Dec 28;12:Article number 22492.
2022-12-15	Skp2-mediated Zeb1 expression facilitates cancer migration by a ubiquitination-independent pathway	Life Sciences. 2022 Dec 15;311(Part A):Article number 121135.
2022-11-06	PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation	Journal of Biomedical Science. 2022 Nov 06;29:Article number 92.
2022-11-01	Revisiting the cerebral hemodynamics of awake, freely moving rats with repeated ketamine self-administration using a miniature photoacoustic imaging system	Neurophotonics. 2022 Nov 01;9(4):Article number 045003.
2022-11	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462-S1463.
2022-10	The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma	Hepatology International. 2022 Oct;16(5):1137-1149.
2022-10	Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study	Clinical Cancer Research. 2022 Oct 3;28(19):4248-4257.
2022-10	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression	Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
2022-09-21	Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer	International Journal of Medical Sciences. 2022 Sep 21;19(10):1615-1627.
2022-09-15	Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin	American Journal of Cancer Research. 2022 Sep 15;12(9):4267-4278.
2022-09	A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study	European Journal of Cancer. 2022 Sep;173:123-132.
2022-09	Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan	Liver Cancer. 2022 Sep;11(5):426-439.
2022-09	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	Annals of Oncology. 2022 Sep;33(7):S565-S566.
2022-07	Toward collaboration among cancer trials groups in Asia: TCOG perspective	Annals of Oncology. 2022 Jul;33(Suppl. 6):S449.
2022-07	Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience	Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.

显示项目26-50 / 510. (共21页) << < 1 2 3 4 5 6 7 8 9 10 > >> 每页显示[10|25|50]项目